<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Aurgalys</title>
	<atom:link href="http://www.aurgalys.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.aurgalys.com</link>
	<description>Entrepreneurs Serving Entrepreneurs</description>
	<lastBuildDate>Wed, 28 Jul 2010 16:40:06 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>July 26, 2010: Aurgalys &amp; CLS issue a new BioAlliance analyst note : Acyclovir Lauriad® to be registered in EU &#8211; Record turnover for S1 2010</title>
		<link>http://www.aurgalys.com/2010/07/july-26-2010-aurgalys-cls-issue-a-new-bioalliance-analyst-note-cyclovir-lauriad%c2%ae-to-be-registered-in-eu-record-turnover-for-s1-2010/</link>
		<comments>http://www.aurgalys.com/2010/07/july-26-2010-aurgalys-cls-issue-a-new-bioalliance-analyst-note-cyclovir-lauriad%c2%ae-to-be-registered-in-eu-record-turnover-for-s1-2010/#comments</comments>
		<pubDate>Wed, 28 Jul 2010 15:16:36 +0000</pubDate>
		<dc:creator>philippe</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1189</guid>
		<description><![CDATA[Aurgalys issued today July26th, 2010, an new analyst report on BioAlliance.

Acyclovir Lauriad®: the Company has engaged discussion with European regulatory agencies and obtained a registration slot
S1 2010 record turnover: €21.3 M versus €4.1 M for the same period in 2009

Since our coverage initiated on June 19th, 2009, the stock increased 61% from €3.44 to €5.53 [...]]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/07/july-26-2010-aurgalys-cls-issue-a-new-bioalliance-analyst-note-cyclovir-lauriad%c2%ae-to-be-registered-in-eu-record-turnover-for-s1-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>June 22, 2010: Aurgalys welcomes new partner and opens offices in Argentina</title>
		<link>http://www.aurgalys.com/2010/06/june-22-2010-aurgalys-welcomes-new-partner-and-opens-offices-in-argentina/</link>
		<comments>http://www.aurgalys.com/2010/06/june-22-2010-aurgalys-welcomes-new-partner-and-opens-offices-in-argentina/#comments</comments>
		<pubDate>Tue, 22 Jun 2010 08:24:41 +0000</pubDate>
		<dc:creator>philippe</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1158</guid>
		<description><![CDATA[Paris, Tel-Aviv, Lausanne, Buenos Aires, June 22, 2010 – Aurgalys, a global provider for life sciences companies through corporate finance, business development and interim management services, is pleased to announce today the appointment of Dr Lila Drittanti as Aurgalys partner and the opening of Latin America offices.
Download our press release here ( english)
Télécharger notre communiqué [...]]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/06/june-22-2010-aurgalys-welcomes-new-partner-and-opens-offices-in-argentina/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioLatina 2010, October 18-20, 2010</title>
		<link>http://www.aurgalys.com/2010/06/biolatina-2010-october-18-20-2010/</link>
		<comments>http://www.aurgalys.com/2010/06/biolatina-2010-october-18-20-2010/#comments</comments>
		<pubDate>Fri, 18 Jun 2010 13:30:58 +0000</pubDate>
		<dc:creator>philippe</dc:creator>
				<category><![CDATA[Meet Us At]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1171</guid>
		<description><![CDATA[

Date: October 18-20, 2010
Title:  BioLatina 2010
Theme(s): Convention and Partnering in Life  Sciences
 Location:  Buenos Aires, Argentina
Meet with: Dr Lila Drittanti, Aurgalys Partner

]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/06/biolatina-2010-october-18-20-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BioEquity Europe 2010, May 19-20, 2010</title>
		<link>http://www.aurgalys.com/2010/05/bioequity-europe-2010-may-19-20-2010/</link>
		<comments>http://www.aurgalys.com/2010/05/bioequity-europe-2010-may-19-20-2010/#comments</comments>
		<pubDate>Tue, 18 May 2010 13:49:44 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[Meet Us At]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1143</guid>
		<description><![CDATA[

Date: May 19-20, 2010
Title:  2010 BioEquity
Theme(s): Convention and Partnering in Life  Sciences
 Location:  Zurich, Switzerland
Meet with: Dr Laurent Choppe, CLS Managing Partner

]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/05/bioequity-europe-2010-may-19-20-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>April 7, 2010: Aurgalys-CLS reitarates BUY recommendation on BioAlliance stock [EuroNext: BIO.FP]</title>
		<link>http://www.aurgalys.com/2010/04/april-7-2010-aurgalys-cls-reitarate-buy-recommendation-on-bioalliance-stock-euronext-bio-fp/</link>
		<comments>http://www.aurgalys.com/2010/04/april-7-2010-aurgalys-cls-reitarate-buy-recommendation-on-bioalliance-stock-euronext-bio-fp/#comments</comments>
		<pubDate>Wed, 07 Apr 2010 16:30:04 +0000</pubDate>
		<dc:creator>philippe</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1122</guid>
		<description><![CDATA[Aurgalys issued today April 7th, 2010, an new analyst report on BioAlliance.
Since our coverage initiated on June 19th, 2009, the stock increased 69% from €3.44 to €5.81 today.
Given the recent Company newsflow with the approval of Setofilm in Europe, the approval of Loramyc in 13 new European countries, making it 26, the new partner Therabel [...]]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/04/april-7-2010-aurgalys-cls-reitarate-buy-recommendation-on-bioalliance-stock-euronext-bio-fp/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>2010 BIO International Convention, May 3-6, 2010</title>
		<link>http://www.aurgalys.com/2010/02/2010-bio-international-convention-may-3-6-2010/</link>
		<comments>http://www.aurgalys.com/2010/02/2010-bio-international-convention-may-3-6-2010/#comments</comments>
		<pubDate>Fri, 05 Feb 2010 15:02:06 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[Meet Us At]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1004</guid>
		<description><![CDATA[Date: May 3-6, 2010
Title:  2010 BIO International Convention
Theme(s): Convention, Exhibition and Partnering in Life Sciences
 Location:  Chicago, IL, USA
Meet with: Dr Philippe Berthon, Aurgalys General Partner
]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/02/2010-bio-international-convention-may-3-6-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Jan 22, 2010: Aurgalys-CLS issues new BioAlliance analyst note [EuroNext: BIO.FP] on a very promising 2010 outlook</title>
		<link>http://www.aurgalys.com/2010/01/jan-22-2010-aurgalys-cls-issues-new-bioalliance-analyst-note-euronext-bio-fp-on-very-promising-2010-outlook/</link>
		<comments>http://www.aurgalys.com/2010/01/jan-22-2010-aurgalys-cls-issues-new-bioalliance-analyst-note-euronext-bio-fp-on-very-promising-2010-outlook/#comments</comments>
		<pubDate>Fri, 22 Jan 2010 17:07:08 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1033</guid>
		<description><![CDATA[Through our analysis we considered that for BioAlliance:

Major milestones were met in 2009
Two products are due to be launched in new markets
Five products currently in clinical development including one which has completed phase III

We recommand a BUY for the stocks with a target price of €12 within one year
Download our BioAlliance Coverage here (available in [...]]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2010/01/jan-22-2010-aurgalys-cls-issues-new-bioalliance-analyst-note-euronext-bio-fp-on-very-promising-2010-outlook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dec 15, 2009: Aurgalys &#8211; CLS has successfully advised Swiss company Evolva  in a CHF21M financial round</title>
		<link>http://www.aurgalys.com/2009/12/dec-15-2009-aurgalys-cls-has-successfully-advised-swiss-company-evolva-in-a-chf21m-financial-round/</link>
		<comments>http://www.aurgalys.com/2009/12/dec-15-2009-aurgalys-cls-has-successfully-advised-swiss-company-evolva-in-a-chf21m-financial-round/#comments</comments>
		<pubDate>Tue, 15 Dec 2009 16:21:50 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=1055</guid>
		<description><![CDATA[ December 15th, 2009,  Aurgalys and Cukierman &#38; Co Life Sciences Cukierman &#38; Co. Life Sciences annouces that they have successfully advised Swiss company Evolva [SIX: EVE] in a CHF21M financial round
Download our  English Press Release here
]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2009/12/dec-15-2009-aurgalys-cls-has-successfully-advised-swiss-company-evolva-in-a-chf21m-financial-round/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>July 10th, 2009: Venture capital and the French paradox</title>
		<link>http://www.aurgalys.com/2009/12/july-10th-2009-venture-capital-and-the-french-paradox/</link>
		<comments>http://www.aurgalys.com/2009/12/july-10th-2009-venture-capital-and-the-french-paradox/#comments</comments>
		<pubDate>Thu, 03 Dec 2009 15:17:13 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[Opinion]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=996</guid>
		<description><![CDATA[July 10th, 2009: Venture capital and the French paradox
Companies are thinking of relocating to France or European Union in order to benefit the private equity funds available there. Philippe Berthon, a board member of France Biotech and Aurgalys General Partner explains.
read more
]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2009/12/july-10th-2009-venture-capital-and-the-french-paradox/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>8th GO4Europe Business Conference, March 15th, 2010</title>
		<link>http://www.aurgalys.com/2009/11/8th-go-4-europe-business-conference-march-15th-2010/</link>
		<comments>http://www.aurgalys.com/2009/11/8th-go-4-europe-business-conference-march-15th-2010/#comments</comments>
		<pubDate>Fri, 27 Nov 2009 10:01:46 +0000</pubDate>
		<dc:creator>esquivel</dc:creator>
				<category><![CDATA[Meet Us At]]></category>

		<guid isPermaLink="false">http://www.aurgalys.com/?p=986</guid>
		<description><![CDATA[Date: March 15, 2010
Title: 8th Go4Europe Business Conference
Theme(s): Strategic and raising funds in Europe
 Location:  Tel-Aviv, Israel
Meet with: Dr Philippe Berthon, Aurgalys General Partner

]]></description>
		<wfw:commentRss>http://www.aurgalys.com/2009/11/8th-go-4-europe-business-conference-march-15th-2010/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
